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Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival im-
provements to the same extent as younger and older patients. We compared changes in survival after
myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL)
among children (n ¼ 981), AYAs (n ¼ 1218), and older adults (n ¼ 469) who underwent transplantation over
3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age
group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did
not change over time for older adults. Survival improvements were primarily related to lower rates of early
treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time.
A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to
describe differences by center type. In this subgroup, there were differences in transplantation practices
among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs
undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.
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14.02.021vulnerable subgroup, in part because survival improvements
over time have lagged behind survival improvements for
older and younger patients with cancer [1,2]. AYAs with
acute lymphoblastic leukemia (ALL) have garnered particular
interest because of apparent survival disparities related to
treatment in pediatric versus adult oncology settings. Several
retrospective analyses have demonstrated superior survival
for AYAs with ALL who are treated on pediatric protocols,
such as a Children’s Cancer Group versus Cancer andTransplantation.
W.A. Wood et al. / Biol Blood Marrow Transplant 20 (2014) 829e836830Leukemia Group B comparison, in which 5-year event-free
survival and overall survival (OS) rates favored AYAs
treated on pediatric studies (63% versus 34%, P < .001 and
67% versus 46%, P < .001 respectively) [3]. The reasons for
these disparities are not entirely clear, though some have
suggested differences in the type and amount of antileu-
kemic drugs in pediatric versus adult treatment protocols [4].
Others have also pointed to differences in the way care is
delivered to AYAs in pediatric versus adult settings, favoring
improved access to care through insurance coverage [5],
better adherence, and a higher proportion of on-time receipt
of therapy in the pediatric setting [6].
In hematopoietic cell transplantation (HCT), outcomes
have improved over time, in part because of improvements
in supportive care and a corresponding reduction in
transplantation-related mortality [7,8]. However, few studies
speciﬁcally addressed outcomes among AYAs undergoing
HCT [9], and it is unclear whether the beneﬁts of improve-
ments in supportive care have been realized equally in the
vulnerable AYA population. For these reasons, we sought to
determine whether outcomes for AYAs after myeloablative
allogeneic HCT for ALL have improved to a similar degree as
those for older and younger patients. Further, we wished to
determine whether signiﬁcant differences existed in care
delivery characteristics associated with pediatric versus
adult HCT settings for AYAs with ALL. We analyzed data
reported to the Center for International Blood and Marrow
Transplant Research (CIBMTR) to address these questions.
METHODS
Data Source and Patients
The CIBMTR is a voluntary working group of more than 450 trans-
plantation centers worldwide that contribute detailed data on allogeneic
and autologous HCTs to a statistical center at the Medical College of Wis-
consin in Milwaukee and the National Marrow Donor Program (NMDP)
Coordinating Center in Minneapolis. Centers are required to report all
consecutive transplantations and patients are followed over time, with
yearly follow-up. Computerized checks for discrepancies, physicians’ review
of submitted data, and on-site audits of participating centers ensure data
quality. Observational studies conducted by the CIBMTR are performed in
compliance with the Privacy Rule as a public health authority and in
compliance with all applicable federal regulations pertaining to the pro-
tection of human research participants as determined by continuous review
of the institutional review board of the NMDP.
For this study, we included patients who had received their ﬁrst allo-
geneic HCT for ALL using either an HLA-identical sibling donor (matched
sibling donor) or unrelated donor (URD) from 1990 to 2007 at a trans-
plantation center in the United States. Only patients who underwent
transplantation after myeloablative conditioning and were in either ﬁrst or
second complete remission (CR) were included in this analysis. Recipients of
umbilical cord blood grafts were excluded. Patients were divided into
3 groups based on age at transplantation: children (<15 years), AYAs (15 to
40 years), and older adults (>40 years), tomatch the recommendedNational
Cancer Institute Progress Review Group age deﬁnition for AYAs [10].
Outcomes and Study Deﬁnitions
The primary objective of this study was to compare change over time in
rates of OS, leukemia-free survival (LFS), relapse, and treatment-related
mortality (TRM) among children, AYAs, and older adults. For OS, death
from any cause was considered an event. LFS was deﬁned as survival in CR
after HCT. Relapse was deﬁned as leukemia recurrence. TRM was deﬁned as
death in CR. All outcomes were assessed from the date of transplantation.
The NMDP classiﬁcation of HLA-matching status was used for URD
recipients (well matched, partially matched, or mismatched) [11]. Where
information was available, cytogenetic risk was classiﬁed as high risk
(t [4,11], t [9,22], t [8,14], hypodiploidy, or near triploidy, or more than
5 cytogenetic abnormalities), normal (normal cytogenetics), or other (any
other abnormality) [12,13].
As a secondary objective, we evaluated whether the type of trans-
plantation center (adult versus pediatric) was associated with OS for a
subgroup of AYAs between 15 and 25 years of age. We used several data
sources to determine whether transplantation centers were primarily adultor pediatric transplantation programs. First, we used information available
from the CIBMTR and the NMDP, where centers report their patients’
characteristics, including age. However, some centers with distinct adult and
pediatric programs report as 1 center to the CIBMTR and/or NMDP. For these
centers, we used data collected as part of a national CIBMTR survey to
designate centers as adult versus pediatric [Navneet Majhail, personal
communication]. Furthermore, we also contacted each “combined center” to
determine (1) whether these centers performed transplantations exclu-
sively for pediatric patients, adult patients, or both; (2) in cases where both
adults and children underwent transplantation at the center, if there were
separate pediatric and adult transplantation teams; and (3) the age cutoff
that a center used to determine whether a patient would be cared for by the
adult or pediatric service. Based on information obtained from these various
above listed sources, centers were classiﬁed as either adult or pediatric.
Statistical Methods
Summaries of patient-, disease-, and treatment-related characteristics
were produced for the 3 age groups. The chi-square test was used to
compare categorical variables, and the Kruskal-Wallis test was used for
continuous variables. Univariate probabilities of OS and LFS were calculated
using the Kaplan-Meier estimator [14]. Probabilities of relapse and TRM
were estimated using a cumulative incidence function method [15]. To
evaluate changes in outcomes over time, we divided the cohort into 3 time
periods based on the year of transplantation (1990 to 1995, 1996 to 2001,
and 2002 to 2007).
Cox proportional hazards models were used to adjust for signiﬁcant
covariates while comparing the 3 age groups. All factors were examined for
proportional hazards using a time-dependent covariate to appropriately
model early versus later events. A backward regression model selection
technique was used to identify signiﬁcant covariates to be included in the
models. The main effects tested in all multivariate analysis models were age
and time period of transplantation. Consistent with the primary study
question, potential interactions between age and time period were also
examined. In addition to age and time period of transplantation, the patient
and disease characteristic covariates considered in the multivariable models
included gender, race/ethnicity, Karnofsky performance status, disease
status, cell of origin (T versus B cell), cytogenetic risk, and time from diag-
nosis to HCT. As time from diagnosis to ﬁrst CR (CR1) was confounded by
disease status (CR1 versus second CR [CR2]), the 2 covariateswere combined
formultivariable analysis (CR1 versus CR2with duration of CR1<36months
versus CR2 with duration of CR1  36 months versus CR2 with duration of
CR1 unknown).
For the subgroup analysis that focused on adult versus pediatric center
comparison for AYAs between 15 and 25 years of age, we describe the
characteristics of patients who underwent transplantation at the 2 types of
center. Univariate probabilities of OS, LFS, TRM, and relapse were analyzed
as described above. Because of limited number of patients, we were not able
to perform multivariable analyses to study the association of center type
with patient outcomes.
All computations were performed using the SAS statistical package (SAS
Institute, Cary, NC). All P values are 2 sided.
RESULTS
Patient Characteristics
In total, 2668 patients with ALL in CR1 or CR2 reported to
the CIBMTR from 1990 to 2007 met the study eligibility
criteria, including 981 children, 1218 AYAs, and 469 older
adults (Table 1). From 1996 to 2007, transplantation volume
increased by 7% in children, 50% in AYAs, and 180% in older
adults. The proportions of patients receiving peripheral
blood stem cell transplants and of patients receiving HCT
using well-matched URD HCT increased over time in all 3 age
groups. The proportions of Hispanic recipients increased
among children and AYAs over time (in children, 6% in the
period from 1990 to 1995 to 17% in the period from 2002 to
2007, and in AYAs, 4% in the period from 1990 to 1995 to 15%
in the period from 2002 to 2007), but remained unchanged
in older adults (5% in the period from 1990 to 1995 to 6% in
the period from 2002 to 2007).
Outcomes Over Time
Univariate analyses for OS, LFS, relapse, and TRM of chil-
dren, AYAs, and older adults over time are presented in
Table 2. Survival was inversely related to age, with older
Table 1
Patient, Disease, and Transplantation Characteristics for Patients Receiving First Myeloablative Allogeneic HCT for ALL
Characteristics Children (<15 yr) AYAs (15-40 yr) Older Adults (>40 yr)
1990-1995 1996-2001 2002-2007 1990-1995 1996-2001 2002-2007 1990-1995 1996-2001 2002-2007
No. of patients 267 343 371 309 362 547 60 106 303
No. of centers 44 59 57 75 103 118 34 49 77
Age at HCT, median (range), yr 7.2 (.5-14.9) 7.6 (.5-14.9) 8.2 (.5-14.9) 23.9 (15.0-39.8) 23.7 (15.0-39.9) 26.2 (15.0-39.9) 44.8 (40.1-58.2) 47.0 (40.0-61.1) 49.1 (40.0-66.2)
Male 175 (66) 196 (57) 230 (62) 198 (64) 227 (63) 356 (65) 37 (62) 51 (48) 158 (52)
Race/ethnicity
Non-Hispanic white 213 (80) 242 (71) 232 (63) 253 (82) 273 (75) 298 (73) 53 (88) 91 (86) 257 (85)
African-American 13 (5) 26 (8) 28 (8) 12 (4) 17 (5) 20 (4) 0 6 (6) 10 (3)
Asian/Paciﬁc Islander 12 (4) 15 (4) 15 (4) 14 (5) 19 (5) 21 (4) 2 (3) 2 (2) 7 (2)
Hispanic 16 (6) 55 (16) 63 (17) 12 (4) 49 (14) 84 (15) 3 (5) 5 (5) 18 (6)
Other/unknown 13 (5) 5 (1) 33 (9) 18 (6) 4 (1) 24 (4) 2 (3) 2 (2) 11 (4)
KPS at HCT
90 238 (89) 293 (85) 307 (83) 240 (78) 273 (75) 383 (70) 43 (72) 75 (71) 186 (60)
<90 27 (10) 45 (13) 20 (5) 65 (21) 84 (23) 122 (22) 17 (28) 29 (27) 94 (31)
Disease status at HCT
CR1 77 (29) 114 (33) 127 (34) 159 (51) 160 (44) 279 (51) 47 (78) 73 (69) 232 (77)
CR2, CR1 duration <36 mo 137 (51) 162 (47) 182 (49) 104 (34) 153 (42) 192 (35) 10 (17) 29 (27) 54 (18)
CR2, CR1 duration  36 mo 37 (14) 57 (17) 52 (14) 35 (11) 42 (12) 53 (10) 2 (3) 3 (3) 13 (4)
CR2, CR1 duration unknown 16 (6) 10 (3) 10 (3) 11 (4) 7 (2) 23 (4) 1 (2) 1 (1) 4 (1)
Time from diagnosis to HCT
<6 mo 44 (16) 75 (22) 90 (24) 105 (34) 83 (23) 180 (33) 33 (55) 39 (37) 153 (50)
6-12 mo 59 (22) 55 (16) 57 (15) 76 (25) 100 (28) 133 (24) 15 (25) 42 (40) 90 (30)
12 mo 164 (61) 213 (62) 224 (60) 128 (41) 179 (49) 234 (43) 12 (20) 25 (24) 60 (20)
Cell of origin
B cell 171 (64) 249 (73) 280 (75) 155 (50) 233 (64) 428 (78) 33 (55) 72 (68) 246 (81)
T cell 30 (11) 31 (9) 60 (16) 55 (18) 55 (15) 83 (15) 7 (12) 6 (6) 26 (9)
Other/unknown 66 (25) 63 (18) 31 (8) 99 (32) 74 (20) 36 (7) 20 (33) 28 (26) 31 (10)
Graft type
Bone marrow 266 (100) 319 (93) 291 (78) 303 (98) 304 (84) 209 (38) 59 (98) 82 (77) 82 (27)
Peripheral blood 1 (<1) 24 (7) 80 (22) 6 (2) 58 (16) 338 (62) 1 (2) 24 (23) 221 (73)
HLA match
HLA-identical sibling 104 (39) 93 (27) 58 (16) 203 (66) 74 (20) 102 (19) 39 (65) 38 (36) 82 (27)
Unrelated, well matched 27 (10) 66 (19) 168 (45) 27 (9) 107 (30) 289 (53) 6 (10) 17 (16) 148 (49)
Unrelated, partially matched 54 (20) 113 (33) 96 (26) 28 (9) 111 (31) 121 (22) 10 (17) 33 (31) 56 (18)
Unrelated, mismatched 81 (30) 66 (19) 46 (12) 49 (16) 68 (19) 27 (5) 5 (8) 17 (16) 11 (4)
Conditioning
TBI/Cy 198 (74) 285 (83) 337 (91) 187 (61) 288 (80) 398 (73) 38 (63) 77 (73) 182 (60)
Cy/Bu 23 (9) 33 (10) 4 (1) 32 (10) 28 (8) 25 (5) 7 (12) 9 (8) 27 (9)
TBI/etoposide 18 (7) 17 (5) 17 (5) 82 (27) 35 (10) 78 (14) 13 (22) 15 (14) 58 (19)
TBI/other 26 (10) 5 (1) 6 (2) 7 (2) 7 (2) 24 (4) 2 (3) 4 (4) 22 (7)
Other 2 (1) 3 (1) 7 (2) 1 (<1) 4 (1) 22 (4) 0 1 (1) 14 (5)
GVHD prophylaxis
CsA þ MTX þ/ other 122 (46) 162 (47) 165 (44) 139 (45) 188 (52) 134 (24) 26 (43) 57 (54) 71 (23)
FK506 þ MTX þ/ other 2 (1) 24 (7) 101 (27) 7 (2) 54 (15) 263 (48) 1 (2) 20 (19) 140 (46)
T cell depletion 66 (25) 96 (28) 57 (16) 46 (15) 73 (20) 31 (5) 15 (25) 14 (13) 19 (7)
Other 77 (29) 61 (18) 48 (19) 117 (38) 47 (15) 119 (23) 18 (30) 15 (15) 73 (26)
ALL indicates acute lymphoblastic leukemia; AYAs, adolescent and young adults; KPS, Karnofsky performance status; HCT, hematopoietic cell transplantation; CR, complete remission; HLA, human leukocyte antigen; TBI, total
body irradiation; Cy, cyclophosphamide; Bu, busulfan; GVHD, graft-versus-host disease; CSA, cyclosporine; MTX, methotrexate.
Data presented are n (%) unless otherwise indicated.
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Table 3
Multivariate Analyses for Outcomes by Time Period and Age Group
Variable Hazard
Ratio
95% Conﬁdence
Intervals
P
Value
Overall survival*
Age group
Children 1.00 - <.001y
AYAs 1.57 1.40-1.77 <.001
Older adults 2.04 1.75-2.39 <.001
Year of transplantation
1990-1995 1.00 - <.001y
1996-2001 (4 mo)z .82 .67-.99 .04
1996-2001 (>4 mo)z 1.21 1.01-1.46 .04
2002-2007 (4 mo)z .44 .36-.54 <.001
2002-2007 (>4 mo)z 1.12 .94-1.33 .22
Leukemia-free survivalx
Age group
Children 1.00 - <.001y
AYAs 1.50 1.34-1.69 <.001
Older adults 1.84 1.58-2.14 <.001
Year of transplantation
1990-1995 1.00 -
1996-2001 (2 mo)z .74 .58-.94 .02y
1996-2001 (>2 mo)z 1.22 1.04-1.43 .02
2002-2007 (2 mo)z .40 .31-.51 <.001
2002-2007 (>2 mo)z 1.06 .91-1.24 .44
Relapsek
Age group
Children 1.00 - <.001y
AYAs ( 12 mo)z 1.08 .89-1.32 .42
AYAs (>12 mo)z 2.09 1.59-2.75 <.001
Older adults 1.28 1.00-1.63 .05
Year of transplantation
1990-1995 1.00 - .08y
1996-2001 1.28 1.03-1.58 .03
2002-2007 1.18 .97-1.45 .10
Treatment-related
mortality{
Age group
Children 1.00 - <.001y
AYAs 1.66 1.42-1.95 <.001
Older adults 2.37 1.94-2.88 <.001
Year of transplantation
1990-1995 1.00 - <.001y
1996-2001 (4 mo)z .79 .64-.97 .03
1996-2002 (>4 mo)z 1.28 .96-1.71 .09
2002-2007 (4 mo)z .42 .34-.52 <.001
2002-2007 (>4 mo)z 1.29 .98-1.70 .07
* Multivariable models adjusted for the following covariates: disease
status, cell of origin, cytogenetic risk, and Karnofsky performance score at
transplantation.
y Overall P value.
z Nonproportional hazards; hazard ratio differed by time since trans-
plantation (eg, 4 months or>4 months for overall survival and treatment-
related mortality).
{ Multivariable models adjusted for the following covariates: cytogenetic
risk, interval from diagnosis to transplantation, and Karnofsky performance
score at transplantation.
x Multivariable models adjusted for the following covariates: disease
status, cell of origin, cytogenetic risk, and Karnofsky performance score at
transplantation.
k Multivariable models adjusted for the following covariates: disease
status.
Table 2
Unadjusted Probability of Outcomes by Time Period and Age Group Five
Years after HCT
Outcome 1990-1995 1996-2001 2002-2007
Overall survival
Children 49 (43-55) 53 (47-58) 58 (53-63)
AYAs 34 (29-40) 34 (29-39) 43 (39-47)
Older adults 41 (29-54) 22 (14-30) 36 (30-41)
Leukemia-free survival
Children 47 (41-53) 33 (43-53) 53 (48-58)
AYAs 33 (28-39) 31 (26-36) 38 (34-43)
Older adults 41 (29-55) 19 (12-27) 33 (28-39)
Relapse
Children 23 (18-28) 26 (21-31) 28 (24-33)
AYAs 24 (19-29) 28 (23-33) 31 (27-35)
Older adults 4 (0-10) 28 (20-37) 26 (21-31)
Treatment-related mortality
Children 30 (25-36) 26 (22-31) 19 (15-23)
AYAs 43 (37-49) 41 (36-46) 31 (27-35)
Older adults 55 (42-68) 53 (44-63) 41 (36-47)
AYAs indicates adolescent and young adults; HCT, hematopoietic cell
transplantation.
Data presented are probability (95% conﬁdence interval).
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who in turn had lower OS and LFS rates than children,
particularly in the 2 most recent time periods. For all time
periods, higher TRM probability estimates were directly
related to increasing age, with AYAs having higher 5-year
TRM than children and adults having higher TRM than
AYAs. The probabilities of relapse were similar across cohorts
for each of the time periods.
Results for multivariate analyses for OS, LFS, relapse, and
TRM are shown in Table 3. After adjusting for patient and
disease characteristics, older age was shown to be associated
with poorer survival (hazard ratio [HR], 2.04 for older adults
and 1.57 for AYAs versus children, P < .001). No signiﬁcant
interactions were observed between age and time period.
Figure 1 displays 5-year adjusted OS probabilities for each
age group over time, highlighting that OS for AYAs improved
and did not lag behind any survival improvements in the
other age groups. Similar ﬁndings were observed for LFS and
TRM, in which older patients again had inferior outcomes
compared with AYAs, who in turn had inferior outcomes
compared with children. Again, there was no signiﬁcant
interaction between age and time period.
For the entire cohort, late relapse rates (>12 months from
HCT) for AYAs were higher than overall relapse rates for
children (HR, 2.1; P < .001), whereas early relapse rates for
AYAs were not signiﬁcantly different than overall relapse
rates for children (HR, 1.1; P ¼ .42). The difference between
overall relapse rates for older adults and those for children
was of borderline signiﬁcance (HR, 1.3; P¼ .05). Relapse rates
after HCT were not signiﬁcantly different in the period from
2002 to 2007 when compared with the period from 1990 to
1995 (HR, 1.2; P ¼ .10).
An analysis of outcomes stratiﬁed by donor type for the
3 age cohorts in the most recent time period, 2002 to 2007,
was also performed, with results presented in Table 4. In
unadjusted outcomes, children maintained superior survival
outcomes to AYAs and older adults, including recipients of
both matched sibling and URD transplants. TRM was higher
in AYAs and in older adults than in children for both types of
transplantations.
Differences in Pediatric versus Adult Centers for AYAs
Table 5 shows transplantation characteristics for 15 to
25-year-old patients who underwent HCT at either apediatric or adult transplantation center. For this analysis,
there were 130 AYAs within this age group who underwent
transplantation at 46 pediatric centers and 92 AYAs who
underwent transplantation at 49 adult centers. OS, LFS,
relapse, and TRM did not appear to differ by center type
(Figure 2), but sample size precluded formal statistical
comparison with adjustment for relevant patient and
transplantation characteristics.
There were several differences between pediatric and
adult centers in baseline patient characteristics and trans-
plantation techniques. AYAs between 15 and 25 years of age
Table 5
Patient Characteristics by Center Type (Pediatric versus Adult) for AYAs Ages
15 to 25 Years Who Received a Myeloablative Allogeneic HCT between 2002
and 2007
Characteristics Pediatric
Center
Adult
Center
P
Value
n (%) n (%)
No. of patients 130 92
No. of centers 46 49
Age at HCT, yr <.001
15-19 106 (82) 22 (24)
20-25 24 (18) 70 (76)
KPS at HCT .005
90 101 (78) 61 (66)
<90 18 (14) 28 (30)
Disease status at HCT .18
CR1 46 (35) 45 (49)
CR2, CR1 duration <36 mo 29 (35) 36 (39)
CR2, CR1 duration 36 mo 18 (14) 7 (8)
CR2, CR1 duration unknown 7 (5) 4 (4)
Interval from diagnosis to CR1, mo .003
<1 54 (48) 21 (25)
1-6 55 (49) 55 (65)
6 4 (4) 8 (10)
Time from diagnosis to HCT, mo .019
<6 26 (20) 30 (33)
6-12 23 (18) 22 (24)
12 81 (62) 40 (43)
Cytogenetic risk .34
High risk 35 (27) 17 (18)
Normal 33 (25) 31 (34)
Other 35 (27) 22 (24)
Not tested/unknown 27 (21) 22 (24)
Graft type <.001
Bone marrow 74 (57) 24 (26)
Peripheral blood 56 (43) 68 (74)
HLA match .11
HLA-identical sibling 21 (16) 19 (21)
Unrelated, well matched 68 (52) 49 (53)
Unrelated, partially matched 26 (20) 22 (24)
Unrelated, mismatched 12 (9) 1 (1)
Unrelated, unknown degree of match 3 (2) 1 (1)
Conditioning .04
TBI/Cy 102 (78) 63 (68)
Cy/Bu 4 (3) 4 (4)
TBI/etoposide 15 (12) 12 (13)
TBI/other 8 (6) 5 (5)
Other 1 (1) 8 (9)
GVHD prophylaxis <.01
CSAþ MTX þ/ other 53 (41) 19 (21)
FK506 þ MTX þ/ other 35 (27) 44 (48)
Figure 1. Five-year adjusted overall survival probabilities for each age group
over time (the lines in the box represent survival probability and the ends of
the box represent 95% conﬁdence intervals).
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Karnofsky performance status (78% with Karnofsky perfor-
mance status  90 in pediatric centers versus 66% in adult
centers, P ¼ .005). In pediatric centers, patients had a shorter
interval from diagnosis to CR1 (P ¼ .003) and had a longer
time from diagnosis to transplantation (P ¼ .02). AYAs who
underwent transplantation at pediatric centers were more
likely to receive bone marrow grafts than AYAs at adult
centers (57% versus 26%, P < .001). AYAs who underwent
transplantation at pediatric centers were more likely to
receive cyclosporine-based graft-versus-host disease
(GVHD) prophylaxis (41% versus 21%, P < .01) and were more
likely to receive cyclophosphamide/total body irradiation
conditioning (78% versus 68%, P ¼ .04).
DISCUSSION
Although survival improvements for AYAs with cancer in
general have lagged behind children and older adults, we
found that survival after transplantation for AYAs improved
over time in parallel to younger patients and more favorably
than older adults. The observation that survival improve-
ments in AYAs did not lag behind other age groups is similarTable 4
Unadjusted Probability of Outcomes by Donor Type and Age Group Five
Years after HCT for the Most Recent Cohort (2002 to 2007)
Outcome Matched Sibling Donor Unrelated Donor
Overall survival
Children 68 (56-81) 56 (50-62)
AYAs 48 (38-59) 42 (37-47)
Older adults 33 (24-46) 37 (30-44)
Leukemia-free survival
Children 61 (49-75) 52 (46-58)
AYAs 34 (34-54) 38 (33-43)
Older adults 31 (23-43) 34 (28-41)
Relapse
Children 34 (21-47) 27 (22-32)
AYAs 31 (22-41) 31 (26-35)
Older adults 29 (19-40) 24 (18-30)
Treatment-related mortality
Children 5 (1-13) 21 (16-26)
AYAs 25 (17-35) 32 (27-37)
Older adults 39 (28-50) 42 (34-49)
AYAs indicates adolescent and young adults; HCT, hematopoietic cell
transplantation.
Data presented are probability (95% conﬁdence interval).
T cell depletion 21 (16) 3 (3)
Other 21 (16) 26 (28)
AYAs indicates adolescent and young adults; KPS, Karnofsky performance
status; HCT, hematopoietic cell transplantation; CR, complete remission;
HLA, human leukocyte antigen; TBI, total body irradiation; Cy, cyclophos-
phamide; Bu, busulfan; GVHD, graft-versus-host disease; CSA, cyclosporine;
MTX, methotrexate.to ﬁndings from a recent study of outcomes after myeloa-
blative transplantation for acute myeloid leukemia [16].
Further, although sample size precluded a formal compari-
son of outcomes for AYAs treated at pediatric versus adult
transplantation centers, in our study, survival rates appeared
similar despite differences in patient selection and trans-
plantation techniques. Taken together, these data provide
reassurance that AYAs with ALL seem to be beneﬁting from
survival improvements in HCT in similar ways to their
younger counterparts and that treatment setting does not
appear, at least preliminarily, to be a major determinant of
outcome.
However, our study demonstrates broader observations
about the inﬂuence of increasing age upon outcomes after
Figure 2. Outcomes for AYAs 15 to 25 years of age who underwent transplantation between 2002 and 2007. (A) Shows overall survival. (B) Shows leukemia-free
survival. (C) Shows treatment-related mortality. (D) Shows relapse.
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riods, children maintained a survival advantage over AYAs
and older adults. Further, survival rates did not appear to
improve in the older adult group over time. It appears that
some of the survival improvement over time in the younger
age groups was attributable to lower rates of TRM, especially
in the early post-transplantation period. These data are
consistent with larger trends in improvements in supportive
care leading to decreased TRM after allogeneic HCT in gen-
eral [7,8]. In the most recent time period, TRM remained
higher for AYAs and for older adults than for children,
including recipients of matched sibling donor transplants.
This observation highlights the continued important contri-
bution of TRM to outcomes after myeloablative trans-
plantation in AYAs and older adults, even in the modern
transplantation era. In this study, wewere not able to analyze
outcomes of GVHD and other potential contributors to TRM,
which need to be addressed by future research. Another
important observationwas the lack of reduction over time in
relapse rates for any age group. This highlights the need for
more research to investigate novel methods to prevent
relapse in these high-risk patients.
The observation that TRM is an important determinant of
survival after myeloablative HCT for ALL is consistent with
published data from large controlled trials. In the Medical
Research Council/Eastern Cooperative Oncology Group
study, the difference in survival between the donor and no-
donor groups was signiﬁcant only in standard-risk patients
because of the higher TRM (36%) in the high-risk patients
undergoing transplantation [17]. In this study, risk was
deﬁned in part by age older than or younger than 35. TheHaemato Oncology Foundation for Adults in Netherlands
(HOVON) study did not categorize risk by age in the same
way as the Medical Research Council/Eastern Cooperative
Oncology Group study, but the authors did conclude that the
greatest beneﬁt of myeloablative HCT for ALL in ﬁrst CR was
likely to be seenwhen TRM rates were less than 20% [18]. An
individual patient data meta-analysis that included both of
the above studies concluded that HCT for ALL in CR1 was
beneﬁcial only in patients younger than 35 years of age
because of higher rates of TRM in older patients [19]. Within
clinical trials, the reasons for differences in TRM as a function
of age are not entirely known and may relate to disease-
related and age-related biology.
In contrast to the above-cited studies based on random-
ized controlled trials, our observational study also highlights
signiﬁcant practice variation in transplantation techniques
for ALL. In pediatric versus adult treatment settings, we
found differences in the characteristics of patients who un-
derwent transplantation and the type of conditioning
regimen, stem cell source, and GVHD prophylaxis used.
These are all key elements of the clinical practice of HCT. Our
study was not designed to assess the impact of these differ-
ences on outcomes. Although superﬁcially these differences
did not appear to impact the outcomes of 15 to 25-year-old
AYAs undergoing transplantation, larger studies would be
needed to conﬁrm this observation. Whether these differ-
ences in practice patterns between pediatric and adult cen-
ters have any impact more generally on outcomes after HCT
for ALL is not known. For example, characteristics of how
patients come to transplantation at pediatric versus adult
centers (time to CR1, time from diagnosis to transplantation)
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if, over time, reduced-intensity transplantation regimens
are used with increasing frequency in adult settings. As
another example, although marrow grafts are used more
frequently in pediatric settings, perhaps because of the
higher proportion of patients with nonmalignant diseases
who underwent transplantation in pediatric centers, marrow
versus peripheral blood use may affect post-transplantation
graft-versus-leukemia or GVHD rates in patients who un-
derwent transplantation for ALL [20]. Additionally, the
distinction between pediatric and adult treatment programs
is only 1 variable that impacts practice patterns [21].
Whether outcomes are inﬂuenced by center-speciﬁc differ-
ences in transplantation techniques among adult centers or
among pediatric centers is also not known.
Our study does have several limitations inherent in a
retrospective analysis with registry-level data. We were un-
able to address issues related to access to HCT or issues
related to caregiver support, ﬁnancial resources, medication
and supportive care adherence, or other factors that may
inﬂuence outcomes after HCT for AYAs and other age groups.
Wewere also unable to address the issue of confounding due
to selection, including the possibility that differences in
explicit or implicit criteria for transplantation might differ by
age group. For example, it is possible that younger patients
may have been more likely to have adverse prognostic fea-
tures at the time of transplantation than older patients, given
differences in practice patterns in the pediatric versus adult
settings. Finally, systematic differences by age group in pre-
transplantation treatment might have affected relative out-
comes among patients who were included in this analysis.
Differences in pre-HCT therapy could conceivably affect TRM,
as pediatric patients in our study had higher pre-HCT Kar-
nofsky performance status than AYA and adult patients, and
the relative contributions of differences in pre-HCT therapy
versus host biological differences to this ﬁnding are not
readily discernible with our data. Differences in pre-HCT
therapy could also contribute to relapse rates. Some of the
patients in the AYA group were likely treated on modiﬁed
pediatric protocols and others on adult protocols, and we
were not able to determine which patients were treated on
which pre-HCT protocols with our available data.
Moving forward, additional studies will be needed to
better understand reasons for persistent differences in late
TRM in relationship to increasing patient age. The impact of
conditioning regimen intensity on TRM and OS for compa-
rable patients, the subject of an ongoing multicenter trial
[22], also requires clariﬁcation. A retrospective CIBMTR study
of patients with Philadelphia chromosomeenegative ALL
who underwent transplantation in ﬁrst or second complete
remission suggested similar age-adjusted survival after
reduced-intensity or full-intensity conditioning [23]. In par-
allel, a more precise understanding of relapse risk as a
function of pre-HCT “adult-like” or “pediatric-like” chemo-
therapy is also needed. After these issues are further clariﬁed,
individualized pre-HCT calculators of TRM and relapse risk
may become possible, similar to the recent development of
post-HCT calculators [24], in turn facilitating the personal-
ized application of transplantation strategies for this disease.
In conclusion, our study shows that improvements in
survival among AYAs undergoing allogeneic HCT for ALL
parallel those seen among younger patients and are more
favorable than those among older adults. However, our study
also demonstrates persistent survival disparities across
increasing age groups that warrant further study.ACKNOWLEDGMENTS
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